Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced ...

Samsung Biologics reported consolidated revenue of KRW 1.3 trillion in the first quarter of 2025, mainly driven by the stable ramp-up of Plant 4 while maintaining the full utilization of Plants 1 ...

FIRST QUARTER 2025 RESULTS Samsung Biologics reported consolidated revenue of KRW 1.3 trillion in the first quarter of 2025, mainly driven by the stable ramp-up of Plant 4 while maintaining the ...

Samsung Biologics' first-quarter revenue grew 37% to KRW 1.3 trillion, driven by higher contribution from the completion of Plant 4 in 2024, strong biosimilar sales, and favorable currency impact.

Samsung Biologics announced on April 28 that it had signed a 737.3 billion won ($5.4 billion) contract to manufacture ...

"We sustained solid momentum in the first quarter, supported by the efficient operations across all our plants and continued partnerships with our clients," said John Rim, CEO and President of Samsung ...

The first wave of Stelara (ustekinumab) biosimilars show steep Wholesale Acquisition Cost discounts greater than 80%, the report finds.

a subsidiary of Samsung Biologics, part owned by parent company Samsung (OTCPK:SSNLF). Collectively, the biosimilar portion of Biogen’s business generated almost $800 million in 2024 and helps ...

According to Samsung’s own website, the Galaxy S25 Edge will, as expected, fall in between the Galaxy S25+ and Galaxy S25 Ultra in terms of its price point. Spotted by Roland Quandt of WinFuture ...

Our free stock report includes 4 warning signs investors should be aware of before investing in MustGrow Biologics. Read for free now. You should always think about risks. Case in point ...